Skip to main content
Erschienen in: Supportive Care in Cancer 1/2022

21.07.2021 | Original Article

Combined local treatments for vertebral metastases with limited epidural extension

verfasst von: Khaled Madani, Arash Najafi, Angela Boticella, Charles Roux, Lambros Tselikas, Alexandre Delpla, Marc Al Ahmar, Thierry de Baere, Frédéric Deschamps

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Vertebral metastases with limited epidural extension (VMLEE) are frequently encountered in cancer patients; they can cause severe and debilitating symptoms including pain and neurological impairment and are usually treated by radiotherapy. In this study, we mainly evaluated the safety of combined local treatments (CLT), associating radiofrequency ablation (RFA) with vertebroplasty and radiotherapy (RT) to treat VMLEE. Also, we aimed to evaluate the short-term efficacy of CLT on bone metastases palliation and long-term prevention of skeletal-related events.

Methods

We retrospectively reviewed treatment complications, pain palliation, and skeletal complications after combined local treatments (CLT) for vertebral metastasis with limited epidural extension (VMLEE).

Results

Eighteen consecutive patients had CLT for 24 VMLEE, between June 2016 and January 2021. No major post-treatment complication was recorded. Nine patients had pain before the initiation of CLT. One month after CLT, only 3 patients had residual pain with a significant decrease of visual analogue scale (VAS), from 7.3 ± 2.4 to 2 ± 0 (p = .008), as well as the mean morphine milligram equivalent dose from 196.6 ± 135.7 to 38.5 ± 26, p = .008. Mean follow-up was 16.7 ± 11.5 months. Only one vertebra showed an increase of a preexisting vertebral fracture. Nine VMLEE had evidence of residual disease, including 2 which resulted in spinal cord compression (2, 11 months).

Conclusion

CLT was safe and effective for pain palliation and long-term prevention of skeletal-related events for treatment of patients with VMLEE. The effectiveness of this combined treatment on tumor control and epidural involvement on the long term needs further investigation.
Literatur
10.
Zurück zum Zitat Basch E, Pugh SL, Dueck AC, Mitchell SA, Berk L, Fogh S, Rogak LJ, Gatewood M, Reeve BB, Mendoza TR, O’Mara AM, Denicoff AM, Minasian LM, Bennett AV, Setser A, Schrag D, Roof K, Moore JK, Gergel T, Stephans K, Rimner A, DeNittis A, Bruner DW (2017) Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. Int J Radiat Oncol Biol Phys 98(2):409–418. https://doi.org/10.1016/j.ijrobp.2017.02.002CrossRefPubMedPubMedCentral Basch E, Pugh SL, Dueck AC, Mitchell SA, Berk L, Fogh S, Rogak LJ, Gatewood M, Reeve BB, Mendoza TR, O’Mara AM, Denicoff AM, Minasian LM, Bennett AV, Setser A, Schrag D, Roof K, Moore JK, Gergel T, Stephans K, Rimner A, DeNittis A, Bruner DW (2017) Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. Int J Radiat Oncol Biol Phys 98(2):409–418. https://​doi.​org/​10.​1016/​j.​ijrobp.​2017.​02.​002CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Wallace AN, Hillen TJ, Friedman MV et al (2017) Percutaneous spinal ablation in a sheep model: protective capacity of an intact cortex, correlation of ablation parameters with ablation zone size, and correlation of postablation MRI and pathologic findings. AJNR Am J Neuroradiol 38(8):1653–1659CrossRef Wallace AN, Hillen TJ, Friedman MV et al (2017) Percutaneous spinal ablation in a sheep model: protective capacity of an intact cortex, correlation of ablation parameters with ablation zone size, and correlation of postablation MRI and pathologic findings. AJNR Am J Neuroradiol 38(8):1653–1659CrossRef
15.
Zurück zum Zitat Nakatsuka A, Yamakado K, Maeda M et al (2004) Radiofrequency ablation combined with bone cement injection for the treatment of bone malignancies. J Vasc Interv Radiol 15(7):707–712CrossRef Nakatsuka A, Yamakado K, Maeda M et al (2004) Radiofrequency ablation combined with bone cement injection for the treatment of bone malignancies. J Vasc Interv Radiol 15(7):707–712CrossRef
16.
Zurück zum Zitat van der Linden E, Kroft LJ, Dijkstra PD (2007) Treatment of vertebral tumor with posterior wall defect using image-guided radiofrequency ablation combined with vertebroplasty: preliminary results in 12 patients. J Vasc Interv Radiol 18(6):741–747CrossRef van der Linden E, Kroft LJ, Dijkstra PD (2007) Treatment of vertebral tumor with posterior wall defect using image-guided radiofrequency ablation combined with vertebroplasty: preliminary results in 12 patients. J Vasc Interv Radiol 18(6):741–747CrossRef
22.
Zurück zum Zitat Greenwood TJ, Wallace A, Friedman MV, Hillen TJ, Robinson CG, Jennings JW (2015) Combined ablation and radiation therapy of spinal metastases: a novel multimodality treatment approach. Pain Physician 18(6):573–581CrossRef Greenwood TJ, Wallace A, Friedman MV, Hillen TJ, Robinson CG, Jennings JW (2015) Combined ablation and radiation therapy of spinal metastases: a novel multimodality treatment approach. Pain Physician 18(6):573–581CrossRef
Metadaten
Titel
Combined local treatments for vertebral metastases with limited epidural extension
verfasst von
Khaled Madani
Arash Najafi
Angela Boticella
Charles Roux
Lambros Tselikas
Alexandre Delpla
Marc Al Ahmar
Thierry de Baere
Frédéric Deschamps
Publikationsdatum
21.07.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2022
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-021-06443-y

Weitere Artikel der Ausgabe 1/2022

Supportive Care in Cancer 1/2022 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.